Entering text into the input field will update the search result below

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q2 2021 Results - Earnings Call Transcript

Aug. 04, 2021 10:29 PM ETSarepta Therapeutics, Inc. (SRPT)
SA Transcripts profile picture
SA Transcripts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2018 Results Conference Call August 4, 2021 4:30 PM ET

Company Participants

Mary Jenkins - Senior Manager, IR

Doug Ingram - President and CEO

Ian Estepan - EVP and CFO

Dallan Murray - SVP and Chief Commercial Officer

Dr. Gilmore O’Neill - EVP, R&D and Chief Medical Officer

Dr. Louise Rodino-Klapac - EVP and Chief Scientific Officer

Conference Call Participants

Gena Wang - Barclays

Tazeen Ahmad - BoA

Brian Abrahams - RBC Capital Markets

Alethia Young - Cantor

Anupam Rama - JP Morgan

Salveen Richter - Goldman Sachs

Brian Skorney - Baird

Gil Blum - Needham & Company

Ritu Baral - Cowen

Difei Yang - Mizuho Securities

John Boyle - William Blair

Max Skor - Morgan Stanley

Joseph Schwartz - SVB Leerink

Ting Liu - UBS

Yun Zhong - BTIG


Good afternoon, ladies and gentlemen, and welcome to the Sarepta Therapeutics Second Quarter 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today’s program is being recorded.

At this time, I’ll turn the call over to Mary Jenkins, Senior Manager, Investor Relations. Please go ahead.

Mary Jenkins

Thank you, operator, and thank you all for joining today’s call.

Earlier today, we released our financial results for the second quarter 2021. The press release is available on our website at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission earlier this afternoon.

Joining us on the call today are Doug Ingram, Ian Estepan; Dallan Murray, Dr. Gilmore O’Neill and Dr. Louise Rodino-Klapac.

After our formal remarks, we’ll open the call for Q&A. I’d like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.